AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
May 25, 2021
31637_dirs_2021-05-24_95dcc104-49a8-4565-88ae-bc60553163cc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-05-21
Reporting Person: Tessier-Lavigne Marc (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-21 | Common Stock | S | 37957 | $60.133 | Disposed | 2551102 | Direct |
| 2021-05-24 | Common Stock | S | 8806 | $60.025 | Disposed | 2542296 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.67 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 3,253 restricted stock units.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.135 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.